



**Supplemental Figure 1.** A second GBM patient derived cell line, GSDC-2, has a similar molecular and functional profile as GSDC. **A.** Western blot analysis of mural and endothelial markers. MDA-MB-231 cells were used as a negative control and HMVEC was a positive control for endothelial markers. Actin is a loading control. **B.** Immunocytochemical analysis of GSDC-2 for the expression of Flk-1, SMa, and VE-cadherin. **C.** Functional analysis of tube formation of GSDC-2. GSDC-2 were treated with an anti-VEGF antibody (Bevacizumab, Beva.) (10  $\mu$ g/ml) or SU1498, a Flk-1 inhibitor, (12.5  $\mu$ M). Tubules were quantified. n=4. \*P<0.05 compared with controls or DMSO treatment.